VVUS is done now but ARNA is trying to catch them as well. ARNA should sell to OREX and use cash for R&D on pipeline if it's that good and VVUS should close the doors and go home. OREX wins and uses money to start up in EU.
Don't be surprised, at least the shorts got what they wanted? Is that what it's all about. What the shorts want. These little bios all get treated the same way. The market them hard when they pass phase 1 & 2 trials and then they let them run to unheard of valuations only to drop them down the 42 - $4 range again because it's harder to market a drug than it is to develop one! Case in point. Just look at VVUS's story over the last three years or so. Two approved drugs in two different categories and a #$%$ poor PPS to show for it.